MA40901A - Anticorps bispécifiques anti-tnf/anti-il-3 - Google Patents

Anticorps bispécifiques anti-tnf/anti-il-3

Info

Publication number
MA40901A
MA40901A MA040901A MA40901A MA40901A MA 40901 A MA40901 A MA 40901A MA 040901 A MA040901 A MA 040901A MA 40901 A MA40901 A MA 40901A MA 40901 A MA40901 A MA 40901A
Authority
MA
Morocco
Prior art keywords
tnf
bispecific antibodies
bispecific
antibodies
Prior art date
Application number
MA040901A
Other languages
English (en)
Inventor
Catherine B Beidler
Jr Rohn L Millican
Songqing Na
Neungseon Seo
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA40901A publication Critical patent/MA40901A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA040901A 2014-11-05 2015-11-02 Anticorps bispécifiques anti-tnf/anti-il-3 MA40901A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462075571P 2014-11-05 2014-11-05

Publications (1)

Publication Number Publication Date
MA40901A true MA40901A (fr) 2017-09-12

Family

ID=54477413

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040901A MA40901A (fr) 2014-11-05 2015-11-02 Anticorps bispécifiques anti-tnf/anti-il-3

Country Status (9)

Country Link
US (1) US9718884B2 (fr)
EP (1) EP3215529A1 (fr)
JP (1) JP2017533705A (fr)
CN (1) CN108064249A (fr)
AR (1) AR102417A1 (fr)
CA (1) CA2959551C (fr)
MA (1) MA40901A (fr)
TW (1) TWI585105B (fr)
WO (1) WO2016073406A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6592600B2 (ja) * 2015-10-30 2019-10-16 イーライ リリー アンド カンパニー 抗ｃｇｒｐ／抗ｉｌ−２３二重特異性抗体及びその使用
TW201902926A (zh) * 2017-05-03 2019-01-16 美商美國禮來大藥廠 抗cgrp／抗il-23雙特異性抗體及其用途
AR112341A1 (es) 2017-08-02 2019-10-16 Lilly Co Eli ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG
CN108640997A (zh) * 2018-05-22 2018-10-12 蔡毓旻 一种双特异性抗体
KR102088789B1 (ko) * 2018-06-20 2020-03-13 인하대학교 산학협력단 항 TNF/IFN scFv-Fc 이중 표적 항체 및 이의 이용
TWI722535B (zh) 2018-08-21 2021-03-21 美商美國禮來大藥廠 測定蛋白質或肽濃度的方法及其用途
KR20210096559A (ko) 2018-11-27 2021-08-05 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 항IL-23p19 항체 및 이의 용도
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
MX2022006880A (es) * 2019-12-06 2022-07-11 Ablynx Nv Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa e il-23.
AU2021272212B2 (en) * 2020-05-13 2025-06-05 Innovent Biologics (Suzhou) Co., Ltd. Formulation comprising anti-il-23p19 antibody, method for preparing same and use thereof
CN115768466A (zh) 2020-05-21 2023-03-07 詹森生物科技公司 用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法
CN112807428B (zh) * 2020-06-12 2024-08-27 江苏荃信生物医药股份有限公司 包含抗人白介素23单克隆抗体的药物组合物
TWI904235B (zh) * 2020-09-10 2025-11-11 美商美國禮來大藥廠 治療性抗體調配物
CN117440967A (zh) * 2020-12-09 2024-01-23 怡诺安有限公司 抗OX40L抗体、抗OX40L/抗TNFα双特异性抗体及其用途
WO2024061288A1 (fr) * 2022-09-21 2024-03-28 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Anticorps ciblant tnf alpha et il-23 et leurs utilisations
WO2025024723A1 (fr) * 2023-07-26 2025-01-30 Sorriso Pharmaceuticals, Inc. Traitement par induction d'il-23 et de tnf-alpha pour des troubles auto-immuns et inflammatoires
WO2025076251A1 (fr) * 2023-10-05 2025-04-10 Sorriso Pharmaceuticals, Inc. Dosages d'inhibiteurs d'il-23 et de tnf-alpha destinés à être utilisés dans des troubles auto-immuns et inflammatoires
CN117534732B (zh) * 2023-11-03 2024-10-22 湖南中晟全肽生物科技股份有限公司 一种抑制il-12与其受体结合的多肽及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009917A1 (fr) 1993-10-07 1995-04-13 The Regents Of The University Of California Anticorps bispecifiques et tetravalents, obtenus par genie genetique
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CA2796140A1 (fr) 1999-03-25 2000-09-28 Jochen Salfeld Anticorps humains de liaison de l'il-12 humaine et methodes de production connexes
ES2637801T3 (es) 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
EP2108660A1 (fr) 2002-10-30 2009-10-14 Genentech, Inc. Inhibition de la production d'il-17
JP4902961B2 (ja) 2002-12-23 2012-03-21 シェーリング コーポレイション 哺乳動物サイトカインの用途；関連試薬
SI1601694T1 (sl) 2003-03-10 2010-01-29 Schering Corp Uporabe IL-23 antagonistov; sorodni reagenti
EP2292758A3 (fr) 2004-12-20 2013-12-25 Merck Sharp & Dohme Corp. Utilisations de cytokine de mammifère, réactifs associés
PT2452694T (pt) 2005-06-30 2019-02-21 Janssen Biotech Inc Anticorpos anti-il-23, composições, métodos e utilizações
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AU2006283194B9 (en) 2005-08-25 2011-02-03 Eli Lilly And Company Anti-IL-23 Antibodies
LT1931710T (lt) 2005-08-31 2017-03-27 Merck Sharp & Dohme Corp. Rekombinantiniai anti-il-23 antikūnai
EP2322219A3 (fr) * 2005-09-01 2013-06-05 Merck Sharp & Dohme Corp. Utilisation des antagonistes IL-23 et IL-17 pour traiter la maladie inflammatoire oculaire auto-immune
EA035459B1 (ru) 2005-12-29 2020-06-19 Сентокор, Инк. Антитело против il-23p19
EP2044118A2 (fr) * 2006-06-13 2009-04-08 Zymogenetics, Inc. Antagonistes d'il-17 et d'il-23 et leurs procédés d'utilisation
JP2010513245A (ja) * 2006-12-14 2010-04-30 アクトジェニックス・エヌブイ 免疫調節を誘起するための結合分子の送達
PL2059534T3 (pl) 2007-02-23 2012-09-28 Merck Sharp & Dohme Przeciwciała Anty-IL-23p19 wytworzone metodą inżynierii genetycznej
CN103396489A (zh) * 2007-02-23 2013-11-20 默沙东公司 工程改造的抗IL-23p19抗体
CN101668531B (zh) * 2007-02-28 2014-05-07 默沙东公司 用于治疗免疫病症的联合治疗
SI2274008T1 (sl) * 2008-03-27 2014-08-29 Zymogenetics, Inc. Sestavki in metode za zaviranje PDGFRBETA in VEGF-A
JP2011523853A (ja) 2008-06-03 2011-08-25 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用
CN102202655B (zh) 2008-08-27 2013-06-19 默沙东公司 基因工程抗IL-23p19抗体的冻干制剂
JP2012507723A (ja) 2008-11-03 2012-03-29 シェーリング コーポレイション 炎症性腸疾患生物マーカーおよび関連治療方法
CA2758964A1 (fr) * 2009-04-16 2010-10-21 Abbott Biotherapeutics Corp. Anticorps anti-tnf-.alpha. et leurs utilisations
WO2011017294A1 (fr) * 2009-08-07 2011-02-10 Schering Corporation Anticorps anti-rankl humain
GB201013975D0 (en) * 2010-08-20 2010-10-06 Imp Innovations Ltd Method of treating desease
CN102958537B (zh) * 2010-04-07 2015-09-16 Abbvie公司 TNF-α结合蛋白
CA2805653A1 (fr) 2010-07-20 2012-01-26 Cephalon Australia Pty Ltd Anticorps specifiques anti-heterodimere il-23
AR084210A1 (es) * 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
TWI588156B (zh) 2011-03-28 2017-06-21 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
MX2014004980A (es) 2011-10-24 2014-09-11 Abbvie Inc Inmunoaglutinantes biespecificos dirigidos contra tnf e il-17.
US20140212425A1 (en) * 2011-12-05 2014-07-31 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
EP2814846B1 (fr) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Récepteurs d'antigène chimères bispécifiques et utilisations thérapeutiques de ceux-ci
AR090626A1 (es) 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos
US20150158943A1 (en) * 2012-06-01 2015-06-11 Momenta Pharmaceuticals, Inc. Methods related to adalimumab
US20150322519A1 (en) 2012-12-21 2015-11-12 Joshua MICELWEE Biomarkers for psoriasis treatment response
TW201444867A (zh) 2013-03-08 2014-12-01 Lilly Co Eli 抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體
AR094877A1 (es) * 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
WO2014143540A1 (fr) 2013-03-15 2014-09-18 Amgen Inc. Méthodes de traitement de la maladie de crohn à l'aide d'un anticorps anti-il-23
MY192824A (en) * 2014-09-03 2022-09-12 Boehringer Ingelheim Int Compound targeting il-23a and tnf-alpha and uses thereof

Also Published As

Publication number Publication date
EP3215529A1 (fr) 2017-09-13
CA2959551C (fr) 2018-09-11
CN108064249A (zh) 2018-05-22
TW201627321A (zh) 2016-08-01
US20160122429A1 (en) 2016-05-05
WO2016073406A1 (fr) 2016-05-12
TWI585105B (zh) 2017-06-01
US9718884B2 (en) 2017-08-01
CA2959551A1 (fr) 2016-05-12
JP2017533705A (ja) 2017-11-16
AR102417A1 (es) 2017-03-01

Similar Documents

Publication Publication Date Title
MA40901A (fr) Anticorps bispécifiques anti-tnf/anti-il-3
CL2018000370A1 (es) Nuevos anticuerpos anti-pd-1
FR25C1022I1 (fr) Anticorps anti-pd-1
EP3387442A4 (fr) Anticorps anti-cd73 humanisés
HUE051700T2 (hu) Anti-PD-1 antitestek
CL2018000281A1 (es) Anticuerpos monoclonales contra bcma
EP3334824A4 (fr) Anticorps anti-pd-1
IL251963A0 (en) Anti-pd-1 antibodies
DK3332006T3 (da) Hidtil ukendte anti-PD-L1-antistoffer
EP3532489A4 (fr) Anticorps monoclonaux neutralisants anti-tl1a
BR112017001385A2 (pt) anticorpos anti-pd-1
DK3344654T3 (da) Anti-lag-3-antistoffer
HUE047929T2 (hu) Kiméra antigén receptor
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
DK3350218T3 (da) Polyomavirus-neutraliserende antistoffer
PT3101032T (pt) Onjugado de anticorpo anti-her2-fármaco
HUE060878T2 (hu) Anti-transztiretin antitestek
IL256097A (en) Antibody epitope
KR20180085002A (ko) 인간화된 항-cll-1 항체
DK3250593T3 (da) Anti-transthyretin-antistoffer
EP3319983C0 (fr) Anticorps de liaison tau
DK3334457T3 (da) Humaniserede anti-CCR7-receptorantistoffer
EP3383915A4 (fr) Anticorps anti-pd-1
PL3215530T3 (pl) Ulepszone przeciwciała anty-il-6
EP3212232A4 (fr) Anticorps bispécifique tétravalent anti-tlr9